Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection

Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas, Laboratório de Genética Celular e Molecular. Belo Horizonte, MG, Brasil.
Unit of Clinical Laboratory Science, University of Biomedical Campus. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy / Migrant and Global Health Research Organization (Mi-HeRo), Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.

Abstract

Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host’s microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response (“gutlung axis”). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia.

Keywords in Portuguese

COVID-19
Disbiose
Eixo intestino-pulmão
Probióticos
Tempestade Sistêmica de Citocinas
Microbioma
SARS-CoV-2

Keywords

Dysbiosis
COVID-19
Gut-lung axis
Probiotics
Systemic cytokine storm
SARS-CoV-2
Targeting Microbiome

Publisher

Karger

Citation

SPAGNOLELLO, Ornella et al. Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection. Chemotherapy, p. 1 - 9, Mar. 2021.

DOI

10.1159/000515344

ISSN

0009-3157

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/51422

Type

Copyright

Open access

Collections

Share

Statistics

Metadata

Author

Affilliation